{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:00:38Z","timestamp":1761872438034,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.clml.2023.10.004","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T11:19:39Z","timestamp":1697282379000},"page":"e50-e57.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcome of Multiple Myeloma Patients With Hepatitis B Surface Antigen: Korean Multiple Myeloma Working Party 2103 Study"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1499-7131","authenticated-orcid":false,"given":"Jun Ho","family":"Yi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Lim","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoo Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Jin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Jin","family":"Yuh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Nam","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Hoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Jeong","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon Ho","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Young","family":"Yhim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5878-8895","authenticated-orcid":false,"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.10.004_bib0001","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.clml.2023.10.004_bib0002","doi-asserted-by":"crossref","first-page":"465","DOI":"10.6004\/jnccn.2011.0045","article-title":"Why, when, and how to prevent hepatitis B virus reactivation in cancer patients undergoing chemotherapy","volume":"9","author":"Keam","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2023.10.004_bib0003","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/jvh.12305","article-title":"Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases","volume":"22","author":"Hwang","year":"2015","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.clml.2023.10.004_bib0004","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/ejh.13839","article-title":"The evolution of immune dysfunction in multiple myeloma","volume":"109","author":"Soekojo","year":"2022","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2023.10.004_bib0005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.bbmt.2017.01.005","article-title":"Impact of hepatitis B core antibody seropositivity on the outcome of autologous hematopoietic stem cell transplantation for multiple myeloma","volume":"23","author":"Varma","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2023.10.004_bib0006","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ajh.23731","article-title":"Clinical profiles of multiple myeloma in Asia\u2014an Asian myeloma Network study","volume":"89","author":"Kim","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2023.10.004_bib0007","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2023.10.004_bib0008","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clml.2023.10.004_bib0009","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1440-1746.2009.05924.x","article-title":"Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease","volume":"24","author":"Wong","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.clml.2023.10.004_bib0010","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3109\/10428194.2014.941833","article-title":"Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant","volume":"56","author":"Li","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.10.004_bib0011","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3109\/10428194.2011.610013","article-title":"High prevalence of hepatitis B virus infection in multiple myeloma","volume":"53","author":"Huang","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.10.004_bib0012","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1186\/s12879-020-05412-w","article-title":"Assessment of infection in newly diagnosed multiple myeloma patients: risk factors and main characteristics","volume":"20","author":"Lin","year":"2020","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.clml.2023.10.004_bib0013","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jhep.2006.02.014","article-title":"Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study","volume":"45","author":"Amin","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.clml.2023.10.004_bib0014","article-title":"High risk of hepatitis B reactivation among patients with acute myeloid leukemia","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2023.10.004_bib0015","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood.V120.21.3738.3738","article-title":"Hepatitis B virus reactivation in chronic myeloid leukemia treated with various tyrosine kinase inhibitors: multicenter, retrospective study","volume":"120","author":"Kim","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.10.004_bib0016","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5114\/aoms\/103606","article-title":"Clinical outcomes of patients with acute lymphoblastic leukemia receiving the hyper-CVAD regimen and assessment of the risk of hepatitis flares due to hepatitis B virus reactivation after chemotherapy","volume":"18","author":"Law","year":"2022","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.clml.2023.10.004_bib0017","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","article-title":"Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports","volume":"22","author":"Evens","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2023.10.004_bib0018","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1111\/liv.12838","article-title":"Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy","volume":"35","author":"Lee","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.clml.2023.10.004_bib0019","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00277-016-2742-7","article-title":"Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents' era","volume":"95","author":"Tsukune","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2023.10.004_bib0020","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41408-017-0002-2","article-title":"Incidence and risk factors of hepatitis B virus reactivation in patients with multiple myeloma in an era with novel agents: a nationwide retrospective study in Japan","volume":"7","author":"Tsukune","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2023.10.004_bib0021","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hep.21024","article-title":"A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization","volume":"43","author":"Jang","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.clml.2023.10.004_bib0022","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3892\/mco.2016.857","article-title":"Analysis of baseline hepatitis B virus DNA levels in chronic hepatitis B patients with non-hematological malignancies prior to the initiation of cancer chemotherapy","volume":"5","author":"Young","year":"2016","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.clml.2023.10.004_bib0023","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"Clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.clml.2023.10.004_bib0024","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.clml.2023.10.004_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/v11111049","article-title":"HBV reactivation in patients undergoing hematopoietic stem cell transplantation: a narrative review","volume":"11","author":"Gentile","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.clml.2023.10.004_bib0026","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nri1842","article-title":"Adoptive immunotherapy for cancer: building on success","volume":"6","author":"Gattinoni","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.clml.2023.10.004_bib0027","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0167-8140(02)00003-8","article-title":"Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer\u2014a retrospective review of Chinese patients and comparison with an historic Western series","volume":"62","author":"Ma","year":"2002","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clml.2023.10.004_bib0028","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jmv.10430","article-title":"Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study","volume":"70","author":"Yeo","year":"2003","journal-title":"J Med Virol"},{"key":"10.1016\/j.clml.2023.10.004_bib0029","first-page":"3035","article-title":"Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy","volume":"24","author":"Hsu","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clml.2023.10.004_bib0030","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/annonc\/mdh430","article-title":"Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy","volume":"15","author":"Yeo","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2023.10.004_bib0031","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1200\/JCO.20.01757","article-title":"Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update","volume":"38","author":"Hwang","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.10.004_bib0032","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cmi.2017.06.023","article-title":"Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper","volume":"23","author":"Sarmati","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clml.2023.10.004_bib0033","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1200\/JCO.2004.05.161","article-title":"Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy","volume":"22","author":"Yeo","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.10.004_bib0034","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1111\/cas.14846","article-title":"Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy","volume":"112","author":"Yamauchi","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2023.10.004_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.685706","article-title":"HBV reactivation during the treatment of non-hodgkin lymphoma and management strategies","volume":"11","author":"Cao","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2023.10.004_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.989258","article-title":"Effect of infection with hepatitis B virus on the survival outcome of diffuse large B-cell lymphoma in the prophylactic antiviral era","volume":"12","author":"Nuersulitan","year":"2022","journal-title":"Front Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502302147X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502302147X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:20Z","timestamp":1761871400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502302147X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S215226502302147X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.10.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome of Multiple Myeloma Patients With Hepatitis B Surface Antigen: Korean Multiple Myeloma Working Party 2103 Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}